FEMY FEMASYS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1339005 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.2%
TTM net income YoY38.7%
TTM EPS YoY175.8%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—
Margins
Gross margin59.9%
Operating margin-929.9%
Net margin-614.7%
FCF margin-877.5%
EBITDA margin-913.3%
Returns
ROE-76.9%
ROA-47.3%
ROIC (approx.)-935.4%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets23.0%
Debt / equity0.00x
Current ratio8.67x
Interest coverage-18.91x
Cash quality & payout
Operating cash flow / net income1.41x
Accruals ratio19.2%
Payout ratio—
Capex / revenue12.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.29M | $1.63M |
| Cost of revenue | $872,400 | $544,903 |
| Gross profit | $1.42M | $1.08M |
| R&D expense | $7.58M | $8.22M |
| SG&A expense | $6.65M | $6.33M |
| Operating income | -$17.59M | -$17.79M |
| Interest expense | $1.89M | $1.60M |
| Pretax income | -$18.63M | -$18.81M |
| Income tax | $1,297 | $9,602 |
| Net income | -$18.63M | -$18.82M |
| EBITDA | -$17.25M | -$17.49M |
| EPS (basic) | -0.47 | -0.85 |
| EPS (diluted) | -0.47 | -0.85 |
| Weighted avg. shares (diluted) | 39.55M | 22.27M |
| Balance sheet | ||
| Cash & equivalents | $9.27M | $3.45M |
| Receivables | $616,600 | $488,373 |
| Inventory | $5.74M | $3.05M |
| Current assets | $16.46M | $8.02M |
| PP&E, net | $1.90M | $1.60M |
| Intangibles | $134,914 | $65,918 |
| Total assets | $20.72M | $12.45M |
| Current liabilities | $3.64M | $8.58M |
| Total liabilities | $14.85M | $10.14M |
| Shareholders' equity | $5.87M | $2.30M |
| Shares outstanding | 2.98M | 23.36M |
| Cash flow statement | ||
| Operating cash flow | -$18.69M | -$19.44M |
| Capital expenditure | $525,007 | $761,706 |
| Free cash flow | -$19.22M | -$20.21M |
| Investing cash flow | -$630,098 | -$847,764 |
| Financing cash flow | $25.14M | $2.03M |
| Depreciation & amortization | $342,034 | $297,318 |
| Stock-based compensation | $790,145 | $444,147 |
| Share buybacks | — | $60,753 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.